According to the international law of new drug research and development and the current situation of China pharmaceutical market, Chipscreen Biotechnology has explored a way to achieve profitable enterprise development by granting patents to international pharmaceutical companies and establishing international clinical joint development while retaining the rights and interests of China products. At the same time, establish a high-level cooperative research business model with multinational pharmaceutical companies. Through this development strategy, the innovative drugs that Chipscreen is developing can not only be listed in China as soon as possible, but also achieve the goal of the original drugs from China entering the global market through the mode of international clinical joint development. This innovative development model —— realizing profit and development through patent authorization, cooperative research and final product listing —— has changed the substantial defect that China local pharmaceutical companies lack original research drugs, and created a precedent from "imitation in China" to "creation in China".
Since its establishment, Chipscreen Biotechnology has made breakthroughs in new drug research and development, intellectual property rights and business development around the establishment of an enterprise development strategy with patents and innovative drugs as its core competitiveness, and won the first place in many industries, making positive contributions to China's innovative drug industry. As a combination of independent innovation and cutting-edge platform technology, China Innovative Medicine Company has been concerned by the industry and media since its establishment, and has been reported by many magazines and media such as Business Weekly, Time Weekly and Nature Biotechnology. He has been invited for many times to give keynote speeches on new drug research and development at major conferences in the international biomedical industry, laying a foundation for the influence of enterprises in the domestic and international pharmaceutical field.